A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.
The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.
Helus Pharma, formerly Cybin, announced a positive topline readout from its first phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). The trial is part of the company's PARADIGM phase 3 program, which tests HLP003 as an adjunctive treatment in adults who have had an inadequate response. The announcement gives no effect size, adverse event data or participant numbers.
Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.
Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.
Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.
DoubleBlind reports that the nonprofit Usona Institute reportedly submitted a New Drug Application to the FDA on November 2, 2026 for its synthetic psilocybin candidate for major depressive disorder (MDD), a filing first reported by Psychedelic Alpha that Usona declined to comment on.
A newly registered trial, PATCH, will evaluate whether psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. The study will assess whether ingesting psilocybin, a naturally occurring psychoactive compound, can enhance treatment outcomes in this population.
Australia's Therapeutic Goods Administration has published interim decisions on proposed amendments to the Poisons Standard from ACMS #48, Joint ACMS-ACCS #42 and ACCS #41, and invited comment by 4 December 2026. The notice covers interim decisions only; the amendments are not final.
Compass Pathways said in its Q3 2026 results that its new drug application for COMP360 psilocybin for treatment-resistant depression (TRD) is nearing completion and will be filed in the next two weeks. The release describes the final NDA submission as nearing completion. The company declined to comment on Usona.
Usona Institute has completed its submission of a new drug application to the US Food and Drug Administration for its psilocybin candidate for major depressive disorder.
NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.
Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.
30 OctFri
Friday
Europe PMC: new psychedelic research papersAI score5555
A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.
Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.
OPEN Foundation summarises a study by Stoliker and colleagues, described as the largest single-site psychedelic neuroimaging study to date, in which 62 healthy adults aged 18 to 55 with no previous meaningful psychedelic experience received a single 19 mg oral dose of psilocybin and underwent fMRI and EEG recordings across rest, guided meditation, music listening and movie viewing.
The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.
Psychopharmacologists Natasha Mason and Eline Haijen-Bongers argue that clinical trials of psychedelics for depression and PTSD rarely account for female sex hormones, in a review in Nature Molecular Psychiatry. They cite a preprint pooling their psychedelic trial data in which women given the same dose responded more strongly and reported greater anxious ego dissolution. The review notes 5-HT2A receptor density rises when estrogen is high.
Compass Pathways chief executive Kabir Nath said the company will "go slow before we go fast" as it prepares to complete a rolling FDA submission this quarter for COMP360.
Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.
A review examines the relationship between classic psychedelics such as LSD, psilocybin and DMT and suicidality, proposing a theoretical double-edged sword model. The authors report that several deaths followed non-medical psychedelic use in unsafe contexts, with unclear suicidal intent, and that rare cases of increased suicidal ideation and behaviours in clinical settings showed no significant differences from placebo groups or established causality.
MAPS attended the FDA's September 14 public hearing on the potential future therapeutic use of psychedelic drugs and plans to submit written testimony on systems readiness.
The U.S. Department of Veterans Affairs launched PIVOT on August 5, a five-site trial of Compass Pathways' COMP360 psilocybin in veterans with treatment-resistant depression.
The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.
Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.
The TGA has extended the closing date for comment on its interim decision on a proposed amendment to the Poisons Standard concerning psilocybine, from ACMS #47, to 31 July 2026. The interim decision follows the June 2025 advisory committee meeting.
The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.